To Top
Image

Animal Health

Animals are nature's treasure; we strive to keep them healthy and protected.
Line

Shaping Global Healthcare by Spearheading the One Health Initiative.

Image

Human Health

Human health being multi-dimensional, our products are aimed for holistic health.

Research & Development

Research and Development is the backbone for product innovation to help improve and extend lives.

Over the years, our R&D team has collaborated with several national and international institutes of repute in the area of vaccines. This has enabled development of top novel products for overall wellbeing.

Learn More

Quality

Quality management is an integral part of our system.

IIL has robust quality management system which follows finest quality standards across its units.

Learn More
  • CSR 01
  • Slide 02
  • Slide 03

Several billion doses

of vaccines sold

IIL Exports

animal and human vaccines to
more than 50 countries

150+

Registered Products

1st Indian tissue culture

rabies vaccine

World’s 1st vaccine

for Porcine cysticercosis

From Managing Director’s Desk

We are truly a research to market company offering cost effective solutions to address various unmet needs in the healthcare business. We are proud of our world class manufacturing capabilities that consistently deliver quality products. We employ best business practices and rank very high amongst our customers. It is our committed people and our endless desire to serve that makes our company very unique and dependable.

Latest News

A veterinary vaccine facility, it will grow Genome Valley’s presence, make jabs for FMD, other emerging diseases, create jobs for 750 people
National Dairy Development Board subsidiary Indian Immunologicals (IIL) will be investing about ₹700 crore to set up a new animal vaccine manufacturing facility in Genome Valley, Hyderabad.

11 October 2022

Indian Immunologicals Limited (IIL) has announced that the company will invest about Rs

11 October 2022

Dr. K. Anand Kumar, Managing Director, Indian Immunologicals Ltd expresses his vi

21 July 2022

.

Image